- Home
- AIRI vs NXTC Comparison
AIRI vs NXTC Comparison
Compare AIRI & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- NXTC
- Stock Information
- Founded
- AIRI 1979
- NXTC 2015
- Country
- AIRI United States
- NXTC United States
- Employees
- AIRI N/A
- NXTC N/A
- Industry
- AIRI Military/Government/Technical
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- NXTC Health Care
- Exchange
- AIRI Nasdaq
- NXTC Nasdaq
- Market Cap
- AIRI 13.4M
- NXTC 13.9M
- IPO Year
- AIRI N/A
- NXTC 2019
- Fundamental
- Price
- AIRI $3.49
- NXTC $5.01
- Analyst Decision
- AIRI
- NXTC Strong Buy
- Analyst Count
- AIRI 0
- NXTC 3
- Target Price
- AIRI N/A
- NXTC $33.00
- AVG Volume (30 Days)
- AIRI 1.5M
- NXTC 20.2K
- Earning Date
- AIRI 08-13-2025
- NXTC 07-31-2025
- Dividend Yield
- AIRI N/A
- NXTC N/A
- EPS Growth
- AIRI N/A
- NXTC N/A
- EPS
- AIRI N/A
- NXTC N/A
- Revenue
- AIRI $53,182,000.00
- NXTC N/A
- Revenue This Year
- AIRI $5.59
- NXTC N/A
- Revenue Next Year
- AIRI $5.00
- NXTC N/A
- P/E Ratio
- AIRI N/A
- NXTC N/A
- Revenue Growth
- AIRI 0.29
- NXTC N/A
- 52 Week Low
- AIRI $3.00
- NXTC $2.69
- 52 Week High
- AIRI $9.44
- NXTC $21.48
- Technical
- Relative Strength Index (RSI)
- AIRI 52.15
- NXTC 47.80
- Support Level
- AIRI $3.31
- NXTC $4.60
- Resistance Level
- AIRI $3.58
- NXTC $5.37
- Average True Range (ATR)
- AIRI 0.17
- NXTC 0.50
- MACD
- AIRI 0.02
- NXTC -0.01
- Stochastic Oscillator
- AIRI 26.88
- NXTC 47.86
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.